TAGRISSO
80mgTAGRISSO80mg
TAGRISSO (osimertinib) 80mg is a third-generation EGFR tyrosine kinase inhibitor for treating EGFR-mutated non-small cell lung cancer, including patients with T790M resistance mutation.
Key Benefits
- Third-generation EGFR TKI overcoming T790M resistance
- Superior CNS penetration for brain metastases
- Nearly doubles progression-free survival vs first-generation EGFR TKIs
- Once-daily oral tablet - convenient administration
- Approved for both first-line and after progression settings
- Adjuvant indication reduces recurrence risk by 80%
Contact Us for Pricing
Get competitive wholesale pricing for TAGRISSO 80mg. Our team is available 24/7.
Direct line: +44 7429 917553
Licensed Supplier
Authorized pharmaceutical distributor
100% Original
Guaranteed authentic products
Worldwide Delivery
International shipping available
24/7 Support
WhatsApp support anytime
How TAGRISSO Works
TAGRISSO works by selectively and irreversibly inhibiting both EGFR-sensitizing mutations and the T790M resistance mutation while sparing wild-type EGFR. This selectivity is crucial because it reduces off-target effects and improves tolerability compared to earlier-generation EGFR inhibitors.
The EGFR pathway plays a critical role in cancer cell growth and survival. When EGFR is mutated (common mutations include exon 19 deletions and L858R), it becomes constantly activated, driving uncontrolled cell proliferation. TAGRISSO binds to the ATP-binding site of mutant EGFR, blocking downstream signaling pathways (RAS-RAF-MEK-ERK and PI3K-AKT) that promote cancer cell survival and proliferation.
TAGRISSO's ability to cross the blood-brain barrier is particularly important because up to 40% of EGFR-mutated lung cancer patients develop brain metastases. The drug achieves therapeutic concentrations in the CNS, providing effective control of both systemic and brain disease.
About TAGRISSO 80mg
TAGRISSO (osimertinib) 80mg by AstraZeneca is a revolutionary targeted therapy that has transformed the treatment landscape for EGFR-mutated non-small cell lung cancer (NSCLC). As a third-generation EGFR tyrosine kinase inhibitor (TKI), TAGRISSO is specifically designed to overcome T790M resistance mutations that develop in patients treated with earlier-generation EGFR inhibitors. TAGRISSO demonstrates exceptional CNS penetration, making it particularly effective against brain metastases—a common and devastating complication of EGFR-mutated lung cancer. Clinical trials have shown TAGRISSO significantly improves progression-free survival compared to first-generation EGFR TKIs when used as first-line treatment. The FLAURA trial demonstrated TAGRISSO nearly doubled median progression-free survival (18.9 months vs 10.2 months) compared to erlotinib or gefitinib. TAGRISSO is also approved as adjuvant treatment after complete tumor resection in early-stage EGFR-mutated NSCLC, reducing recurrence risk by 80%. As an established pharmaceutical supplier in Turkey, we provide authentic AstraZeneca TAGRISSO with full documentation and competitive pricing for hospitals, oncology clinics, and distributors worldwide.
Common Uses
- First-line metastatic EGFR-mutated NSCLC
- EGFR T790M mutation-positive NSCLC after prior TKI
- Adjuvant treatment for early-stage EGFR-mutated NSCLC
- NSCLC with brain metastases
- Locally advanced EGFR-mutated NSCLC
Dosage Information
Recommended Dosage:
Adjuvant Treatment (after surgery):
Dose Modifications:
Missed Dose:
Special Populations:
Always consult with a qualified healthcare professional for proper dosing. This information is for reference only.
Storage & Handling
Store TAGRISSO tablets at 25°C (77°F); excursions permitted to 15-30°C (59-86°F). Store in original package until ready to use to protect from moisture.
No special cold chain requirements. Keep out of reach of children. Do not use tablets if the blister is opened or damaged.
We ensure proper cold chain handling during shipping to maintain product integrity.
Frequently Asked Questions About TAGRISSO
Find answers to common questions about ordering, pricing, and shipping.
Related Oncology Medications Products
Explore more oncology medications medications from our catalog
